Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
165,547,872
-
Total 13F shares
-
35,811,948
-
Share change
-
+494,578
-
Total reported value
-
$264,247,175
-
Price per share
-
$7.38
-
Number of holders
-
110
-
Value change
-
+$883,687
-
Number of buys
-
58
-
Number of sells
-
47
Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q3 2019
As of 30 Sep 2019,
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) was held by
110 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
35,811,948 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., PERCEPTIVE ADVISORS LLC, VICTORY CAPITAL MANAGEMENT INC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, BVF INC/IL, STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, and RTW INVESTMENTS, LP.
This page lists
110
institutional shareholders reporting positions in this security
for the Q3 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.